WallStSmart

AbbVie Inc (ABBV)vsBank of Montreal (BMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 88% more annual revenue ($62.82B vs $33.48B). BMO leads profitability with a 27.1% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. BMO earns a higher WallStSmart Score of 73/100 (B).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

BMO

Strong Buy

73

out of 100

Grade: B

Growth: 8.0Profit: 7.5Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-20.5%)

Margin of Safety

-20.5%

Fair Value

$168.19

Current Price

$201.55

$33.36 premium

UndervaluedFair: $168.19Overvalued

Intrinsic value data unavailable for BMO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$358.55B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

BMO6 strengths · Avg: 8.7/10
Operating MarginProfitability
39.9%10/10

Strong operational efficiency at 39.9%

Market CapQuality
$109.28B9/10

Large-cap with strong market position

Profit MarginProfitability
27.1%9/10

Keeps 27 of every $100 in revenue as profit

P/E RatioValuation
17.6x8/10

Attractively priced relative to earnings

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$6.95B8/10

Generating 7.0B in free cash flow

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
98.9x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.8%2/10

Earnings declined 45.8%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

BMO1 concerns · Avg: 4.0/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : BMO

The strongest argument for BMO centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 27.1% and operating margin at 39.9%.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.

Bear Case : BMO

The primary concerns for BMO are PEG Ratio.

Key Dynamics to Monitor

ABBV profiles as a value stock while BMO is a mature play — different risk/reward profiles.

BMO carries more volatility with a beta of 1.17 — expect wider price swings.

ABBV is growing revenue faster at 12.4% — sustainability is the question.

BMO generates stronger free cash flow (7.0B), providing more financial flexibility.

Bottom Line

BMO scores higher overall (73/100 vs 63/100), backed by strong 27.1% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Bank of Montreal

FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA

Bank of Montreal offers diversified financial services primarily in North America. The company is headquartered in Montreal, Canada.

Want to dig deeper into these stocks?